{"denoms":[{"counts":[{"groupId":"BG000","value":"5"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"6"},{"groupId":"BG003","value":"5"},{"groupId":"BG004","value":"6"},{"groupId":"BG005","value":"14"},{"groupId":"BG006","value":"4"},{"groupId":"BG007","value":"45"}],"units":"Participants"}],"groups":[{"description":"Participants with normal renal function (defined as creatinine clearance \\> 80 mL/min/1.73m\\^2) received a single subcutaneous dose of azacitidine 25 mg/m\\^2 on Day 1.","id":"BG000","title":"Azacitidine 25 mg/m^2"},{"description":"Participants with normal renal function received a single subcutaneous dose of azacitidine 50 mg/m\\^2 on Day 1.","id":"BG001","title":"Azacitidine 50 mg/m^2"},{"description":"Participants with normal renal function received subcutaneous doses of azacitidine 75 mg/m\\^2 on Days 1 to 5.","id":"BG002","title":"Azacitidine 75 mg/m^2"},{"description":"Participants with normal renal function received a single subcutaneous dose of azacitidine 100 mg/m\\^2 on Day 1.","id":"BG003","title":"Azacitidine 100 mg/m^2"},{"description":"Participants with severe renal impairment (RI; defined as creatinine clearance \\< 30 mL/min/1.73 m\\^2) received subcutaneous doses of azacitidine 75 mg/m\\^2 on Days 1 to 5.","id":"BG004","title":"Severe RI: Azacitidine 75 mg/m^2"},{"description":"Participants with normal renal function (RF) received up to 6 cycles of treatment with 75 mg/m\\^2 azacitidine daily on Days 1-7 of each 28-day cycle.","id":"BG005","title":"Extension Phase: Normal RF"},{"description":"Participants with severe renal impairment (RI) received up to 6 cycles of treatment with 75 mg/m\\^2 azacitidine daily on Days 1-7 of each 28-day cycle.","id":"BG006","title":"Extension Phase: Severe RI"},{"description":"Total of all reporting groups","id":"BG007","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"3.78","value":"67.6"},{"groupId":"BG001","spread":"9.63","value":"64.6"},{"groupId":"BG002","spread":"10.19","value":"53.5"},{"groupId":"BG003","spread":"12.02","value":"57.0"},{"groupId":"BG004","spread":"12.58","value":"74.5"},{"comment":"Data for provided initial treatment period arms only","groupId":"BG005","spread":"NA","value":"NA"},{"comment":"Data provided for initial treatment period arms only","groupId":"BG006","spread":"NA","value":"NA"},{"groupId":"BG007","spread":"12.32","value":"63.5"}]}],"title":"Initial Treatment Period"},{"categories":[{"measurements":[{"comment":"Data provided for extension treatment period arms only","groupId":"BG000","spread":"NA","value":"NA"},{"comment":"Data provided for extension treatment period arms only","groupId":"BG001","spread":"NA","value":"NA"},{"comment":"Data provided for extension treatment period arms only","groupId":"BG002","spread":"NA","value":"NA"},{"comment":"Data provided for extension treatment period arms only","groupId":"BG003","spread":"NA","value":"NA"},{"comment":"Data provided for extension treatment period arms only","groupId":"BG004","spread":"NA","value":"NA"},{"groupId":"BG005","spread":"9.52","value":"60.6"},{"groupId":"BG006","spread":"11.0","value":"68.8"},{"groupId":"BG007","spread":"10.15","value":"62.4"}]}],"title":"Extension Treatment Period"}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"3"},{"groupId":"BG003","value":"4"},{"groupId":"BG004","value":"3"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"16"}]}],"title":"Female"},{"categories":[{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"3"},{"groupId":"BG003","value":"1"},{"groupId":"BG004","value":"3"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"11"}]}],"title":"Male"}],"description":"Data provided for initial treatment phase groups only.","paramType":"NUMBER","title":"Sex/Gender, Customized","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"2"},{"groupId":"BG004","value":"2"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"8"}]}],"title":"Black"},{"categories":[{"measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"5"},{"groupId":"BG003","value":"3"},{"groupId":"BG004","value":"4"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"19"}]}],"title":"White"}],"description":"Data provided for initial treatment phase groups only.","paramType":"NUMBER","title":"Race/Ethnicity, Customized","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"5"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"6"},{"groupId":"BG003","value":"5"},{"groupId":"BG004","value":"6"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"27"}]}],"title":"United States"}],"description":"Data provided for initial treatment phase groups only.","paramType":"NUMBER","title":"Region of Enrollment","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"8"},{"groupId":"BG006","value":"2"},{"groupId":"BG007","value":"10"}]}],"title":"Female"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"6"},{"groupId":"BG006","value":"2"},{"groupId":"BG007","value":"8"}]}],"title":"Male"}],"paramType":"NUMBER","title":"Gender of Extension Period Participants","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"5"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"5"}]}],"title":"Black"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"9"},{"groupId":"BG006","value":"4"},{"groupId":"BG007","value":"13"}]}],"title":"White"}],"paramType":"NUMBER","title":"Race: Extension Phase","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"2"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"7"}]}],"title":"0"},{"categories":[{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"4"},{"groupId":"BG003","value":"5"},{"groupId":"BG004","value":"3"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"18"}]}],"title":"1"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"1"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"2"}]}],"title":"2"}],"description":"Scale used by doctors and researchers to assess how a patient's disease is progressing, assess how the disease affects the daily living abilities of the patient, and determine appropriate treatment and prognosis. 0 = fully active, no restrictions; 1 = restricted but ambulatory and capable of light work; 2 = ambulatory and capable of self-care but unable to work. 3 = Capable of only limited self care, confined to bed or chair more than 50% of waking hours. 4 = Completely disabled. Cannot carry on any self care. Totally confined to bed or chair. 5 = Dead.","paramType":"NUMBER","title":"Eastern Cooperative Oncology Group (ECOG) Performance Status: Initial Treatment Phase","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"2"},{"groupId":"BG006","value":"1"},{"groupId":"BG007","value":"3"}]}],"title":"0"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"11"},{"groupId":"BG006","value":"3"},{"groupId":"BG007","value":"14"}]}],"title":"1"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"1"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"1"}]}],"title":"2"}],"paramType":"NUMBER","title":"Eastern Cooperative Oncology Group (ECOG) Performance Status: Extension Phase","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"0.20","value":"2.0"},{"groupId":"BG001","spread":"0.28","value":"1.9"},{"groupId":"BG002","spread":"0.42","value":"1.9"},{"groupId":"BG003","spread":"0.15","value":"1.6"},{"groupId":"BG004","spread":"0.15","value":"1.8"},{"comment":"Data provided for initial treatment period arms only","groupId":"BG005","spread":"NA","value":"NA"},{"comment":"Data provided for initial treatment period arms only","groupId":"BG006","spread":"NA","value":"NA"},{"groupId":"BG007","spread":"0.27","value":"1.9"}]}],"title":"Initial Treatment Period"},{"categories":[{"measurements":[{"comment":"Data provided for extension treatment period arms only","groupId":"BG000","spread":"NA","value":"NA"},{"comment":"Data provided for extension treatment period arms only","groupId":"BG001","spread":"NA","value":"NA"},{"comment":"Data provided for extension treatment period arms only","groupId":"BG002","spread":"NA","value":"NA"},{"comment":"Data provided for extension treatment period arms only","groupId":"BG003","spread":"NA","value":"NA"},{"comment":"Data provided for extension treatment period arms only","groupId":"BG004","spread":"NA","value":"NA"},{"groupId":"BG005","spread":"0.35","value":"1.9"},{"groupId":"BG006","spread":"0.06","value":"1.9"},{"groupId":"BG007","spread":"0.31","value":"1.9"}]}],"title":"Extension Period"}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Body Surface Area (BSA)","unitOfMeasure":"m^2"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"1"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"2"}]}],"title":"Myelodysplastic syndrome-RA"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"1"}]}],"title":"Myelodysplastic syndrome-RARS"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"2"}]}],"title":"Myelodysplastic syndrome-RAEB-T"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"1"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"1"}]}],"title":"Chronic myelomonocytic leukemia"},{"categories":[{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"5"},{"groupId":"BG003","value":"5"},{"groupId":"BG004","value":"4"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"20"}]}],"title":"Solid tumor"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"1"}]}],"title":"Multiple myeloma"}],"description":"MDS = myelodysplastic syndrome; MM = multiple myeloma; RA = refractory anemia; RAEB-T = refractory anemia with excess blasts in transformation; RARS = refractory anemia with ringed sideroblasts; CMML = chronic myelomonocytic leukemia.","paramType":"NUMBER","title":"Cancer Diagnosis: Initial Treatment Phase","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"1"},{"groupId":"BG007","value":"1"}]}],"title":"Myelodysplastic syndrome-RA"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"1"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"1"}]}],"title":"Myelodysplastic syndrome-RARS"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"1"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"1"}]}],"title":"Myelodysplastic syndrome-RAEB-T"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"}]}],"title":"Chronic myelomonocytic leukemia"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"12"},{"groupId":"BG006","value":"3"},{"groupId":"BG007","value":"15"}]}],"title":"Solid tumor"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"}]}],"title":"Multiple myeloma"}],"paramType":"NUMBER","title":"Cancer Diagnosis: Extension Phase","unitOfMeasure":"participants"}],"populationDescription":"Safety population. The total number of participants in the study was 27; 18 continued treatment in the extension phase."}